Inhibition of tumor angiogenesis by globotriaosylceramide immunotargeting

Current antiangiogenic immunotherapeutic strategies mainly focus on the blockade of circulating cytokines or receptors that are overexpressed by endothelial cells. We proposed globotriaosylceramide (Gb3) as a viable alternative target for antiangiogenic therapies. In this setting, we developed an an...

Descripción completa

Detalles Bibliográficos
Autores principales: Birklé, Stéphane, Desselle, Ariane, Chaumette, Tanguy, Gaugler, Marie-Hélène, Cochonneau, Denis, Fleurence, Julien, Dubois, Nolwenn, Hulin, Philippe, Aubry, Jacques, Paris, François
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2013
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3654593/
https://www.ncbi.nlm.nih.gov/pubmed/23734323
http://dx.doi.org/10.4161/onci.23700
_version_ 1782269587917635584
author Birklé, Stéphane
Desselle, Ariane
Chaumette, Tanguy
Gaugler, Marie-Hélène
Cochonneau, Denis
Fleurence, Julien
Dubois, Nolwenn
Hulin, Philippe
Aubry, Jacques
Paris, François
author_facet Birklé, Stéphane
Desselle, Ariane
Chaumette, Tanguy
Gaugler, Marie-Hélène
Cochonneau, Denis
Fleurence, Julien
Dubois, Nolwenn
Hulin, Philippe
Aubry, Jacques
Paris, François
author_sort Birklé, Stéphane
collection PubMed
description Current antiangiogenic immunotherapeutic strategies mainly focus on the blockade of circulating cytokines or receptors that are overexpressed by endothelial cells. We proposed globotriaosylceramide (Gb3) as a viable alternative target for antiangiogenic therapies. In this setting, we developed an anti-Gb3 antibody and validated its therapeutic efficacy in metastatic tumor models.
format Online
Article
Text
id pubmed-3654593
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Landes Bioscience
record_format MEDLINE/PubMed
spelling pubmed-36545932013-06-03 Inhibition of tumor angiogenesis by globotriaosylceramide immunotargeting Birklé, Stéphane Desselle, Ariane Chaumette, Tanguy Gaugler, Marie-Hélène Cochonneau, Denis Fleurence, Julien Dubois, Nolwenn Hulin, Philippe Aubry, Jacques Paris, François Oncoimmunology Author's View Current antiangiogenic immunotherapeutic strategies mainly focus on the blockade of circulating cytokines or receptors that are overexpressed by endothelial cells. We proposed globotriaosylceramide (Gb3) as a viable alternative target for antiangiogenic therapies. In this setting, we developed an anti-Gb3 antibody and validated its therapeutic efficacy in metastatic tumor models. Landes Bioscience 2013-04-01 2013-04-01 /pmc/articles/PMC3654593/ /pubmed/23734323 http://dx.doi.org/10.4161/onci.23700 Text en Copyright © 2013 Landes Bioscience http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Author's View
Birklé, Stéphane
Desselle, Ariane
Chaumette, Tanguy
Gaugler, Marie-Hélène
Cochonneau, Denis
Fleurence, Julien
Dubois, Nolwenn
Hulin, Philippe
Aubry, Jacques
Paris, François
Inhibition of tumor angiogenesis by globotriaosylceramide immunotargeting
title Inhibition of tumor angiogenesis by globotriaosylceramide immunotargeting
title_full Inhibition of tumor angiogenesis by globotriaosylceramide immunotargeting
title_fullStr Inhibition of tumor angiogenesis by globotriaosylceramide immunotargeting
title_full_unstemmed Inhibition of tumor angiogenesis by globotriaosylceramide immunotargeting
title_short Inhibition of tumor angiogenesis by globotriaosylceramide immunotargeting
title_sort inhibition of tumor angiogenesis by globotriaosylceramide immunotargeting
topic Author's View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3654593/
https://www.ncbi.nlm.nih.gov/pubmed/23734323
http://dx.doi.org/10.4161/onci.23700
work_keys_str_mv AT birklestephane inhibitionoftumorangiogenesisbyglobotriaosylceramideimmunotargeting
AT desselleariane inhibitionoftumorangiogenesisbyglobotriaosylceramideimmunotargeting
AT chaumettetanguy inhibitionoftumorangiogenesisbyglobotriaosylceramideimmunotargeting
AT gauglermariehelene inhibitionoftumorangiogenesisbyglobotriaosylceramideimmunotargeting
AT cochonneaudenis inhibitionoftumorangiogenesisbyglobotriaosylceramideimmunotargeting
AT fleurencejulien inhibitionoftumorangiogenesisbyglobotriaosylceramideimmunotargeting
AT duboisnolwenn inhibitionoftumorangiogenesisbyglobotriaosylceramideimmunotargeting
AT hulinphilippe inhibitionoftumorangiogenesisbyglobotriaosylceramideimmunotargeting
AT aubryjacques inhibitionoftumorangiogenesisbyglobotriaosylceramideimmunotargeting
AT parisfrancois inhibitionoftumorangiogenesisbyglobotriaosylceramideimmunotargeting

Ejemplares similares